DSS Inc. Announces Debt Conversion Agreement with Impact Biomedical, Settling $12M Debt for Common Shares

Reuters07-31

<a href="https://laohu8.com/S/DSS">DSS Inc</a>. Announces Debt Conversion Agreement with <a href="https://laohu8.com/S/IBO">Impact Biomedical</a>, Settling $12M Debt for Common Shares

On July 21, 2025, DSS, Inc. announced the successful execution of a Debt Conversion Agreement with Impact Biomedical Inc. This agreement involves the conversion of all outstanding debt owed by Impact, originally amounting to $12 million under a revolving promissory note, into 31,939,778 shares of Impact's common stock. This strategic move effectively settles the debt, including any additional financial or operational support extended by DSS or its affiliates, marking a significant step in DSS's financial strategy. The shares, valued at $0.001 per share, now constitute full and final satisfaction of all amounts owed, showcasing DSS's commitment to innovative financial solutions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dss Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-021548), on July 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2555202446?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-31 04:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555202446","market":"nz","top_or_hot":-1,"title":"DSS Inc. Announces Debt Conversion Agreement with Impact Biomedical, Settling $12M Debt for Common Shares","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/DSS\">DSS Inc</a>. Announces Debt Conversion Agreement with <a href=\"https://laohu8.com/S/IBO\">Impact Biomedical</a>, Settling $12M Debt for Common Shares\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        On July 21, 2025, DSS, Inc. announced the successful execution of a Debt Conversion Agreement with Impact Biomedical Inc. This agreement involves the conversion of all outstanding debt owed by Impact, originally amounting to $12 million under a revolving promissory note, into 31,939,778 shares of Impact's common stock. This strategic move effectively settles the debt, including any additional financial or operational support extended by DSS or its affiliates, marking a significant step in DSS's financial strategy. The shares, valued at $0.001 per share, now constitute full and final satisfaction of all amounts owed, showcasing DSS's commitment to innovative financial solutions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dss Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-021548), on July 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DSS Inc. Announces Debt Conversion Agreement with Impact Biomedical, Settling $12M Debt for Common Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDSS Inc. Announces Debt Conversion Agreement with Impact Biomedical, Settling $12M Debt for Common Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-31 04:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/DSS\">DSS Inc</a>. Announces Debt Conversion Agreement with <a href=\"https://laohu8.com/S/IBO\">Impact Biomedical</a>, Settling $12M Debt for Common Shares\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        On July 21, 2025, DSS, Inc. announced the successful execution of a Debt Conversion Agreement with Impact Biomedical Inc. This agreement involves the conversion of all outstanding debt owed by Impact, originally amounting to $12 million under a revolving promissory note, into 31,939,778 shares of Impact's common stock. This strategic move effectively settles the debt, including any additional financial or operational support extended by DSS or its affiliates, marking a significant step in DSS's financial strategy. The shares, valued at $0.001 per share, now constitute full and final satisfaction of all amounts owed, showcasing DSS's commitment to innovative financial solutions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dss Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-021548), on July 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4563","symbol_name":"昨日强势股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nNDL3bBlZY:1","article_id":"2555202446","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555202446","pubTimestamp":1753906453,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"On July 21, 2025, DSS, Inc. announced the successful execution of a Debt Conversion Agreement with Impact Biomedical Inc. This agreement involves the conversion of all outstanding debt owed by Impact, originally amounting to $12 million under a revolving promissory note, into 31,939,778 shares of Impact's common stock. This strategic move effectively settles the debt, including any additional financial or operational support extended by DSS or its affiliates, marking a significant step in DSS's financial strategy. The shares, valued at $0.001 per share, now constitute full and final satisfaction of all amounts owed, showcasing DSS's commitment to innovative financial solutions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dss Inc. pu","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4563":"昨日强势股","BK4087":"商业印刷","BK4024":"房地产开发","IBO":"Impact Biomedical, Inc.","BK4007":"制药","DSS":"DSS Inc","AEI":"Alset EHome International Inc."},"translate_title":"DSS Inc.宣布与Impact Biomedical达成债务转换协议，解决1200万美元普通股债务","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DSS":0.9,"AEI":0.9,"IBO":0.9},"content_text":"DSS Inc. Announces Debt Conversion Agreement with Impact Biomedical, Settling $12M Debt for Common Shares\n    \n\n        On July 21, 2025, DSS, Inc. announced the successful execution of a Debt Conversion Agreement with Impact Biomedical Inc. This agreement involves the conversion of all outstanding debt owed by Impact, originally amounting to $12 million under a revolving promissory note, into 31,939,778 shares of Impact's common stock. This strategic move effectively settles the debt, including any additional financial or operational support extended by DSS or its affiliates, marking a significant step in DSS's financial strategy. The shares, valued at $0.001 per share, now constitute full and final satisfaction of all amounts owed, showcasing DSS's commitment to innovative financial solutions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dss Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-021548), on July 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2555202446","isCrawlerRequest":true}